We were able to validate our findings in DLBCL using available data from the Chapuy et al.25 study which reported 6q or 6q23.3 loss and MYD88 mutation in n = 304 patients (p < 0.0001). Here, MYD88 is linked to diffuse large B-cell lymphoma.